Sciex Diagnostics, the in vitro diagnostics (IVD) division of Sciex, has announced a joint venture with Zhejiang Dian Diagnostics (Dian).
Photo Credit: zhu difeng/Shutterstock.com
Sciex Diagnostics, the in vitro diagnostics (IVD) division of Sciex, has announced a joint venture with Zhejiang Dian Diagnostics (Dian). A supplier of medical and diagnostic products and services in China, Zhejiang Dian Diagnostics will partner with Sciex in establishing a site in Hangzhou, China, to develop, register, manufacture, and commercialize Class I, II, and III in vitro diagnostic reagents for Sciex’s liquid chromatography tandem mass spectrometry (LC–MS/MS) system, which was approved by the China Food and Drug Administration (CFDA) earlier this year.
The venture intends to address the lack of readily available IVD assays for Chinese hospital laboratories, a situation that continues to hinder the progress of clinical laboratories across the country. The combination of Sciex’s chromatography and assay resources with Dian’s laboratory network, cold chain logistics, and China-IVD manufacturing experience is expected to quickly address these issues and accelerate China’s clinical laboratory programme.
“Modern-day China contends with many lifestyle factors that can lead to illness. Our aim is to provide wellness testing resources that can help hospitals identify potential health risks before they become chronic,” said Inese Lowenstein, President of Sciex.
“Dian has established many product channels with its wide coverage of high-end medical resources, and this venture will further enrich their existing in vitro diagnostic product lines to enable hospital labs to expand their testing capabilities, and perform tests that they previously were not able to,” said Lowenstein.
“It is an important decision and major breakthrough for Dian to collaborate with Sciex,” said Hai bin Chen, Chairman of Zhenjang Dian Diagnostics. “This joint venture is the first of its kind in China, and by also working closely with CFDA and Health and Family Planning Commission, we believe it will have a profound influence on the future of wellness and diagnostic testing in China,” continued Chen.
A ceremony to celebrate the venture took place at Zhejiang Dian Diagnostics headquarters in Hangzhou, China, attended by Sciex Senior Leadership Executives.
For more information please visit: www.sciex.com
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.